stock.adobe.photo.com/Popelniushka According to a new deal, AGC Biologics wil manufacture AAVantgarde’s dual AAV gene therapies for inherited retinal diseases using the high-yield BravoAAV™ suspension platform.
ADVERTISEMENT
According to a new deal, AGC Biologics wil manufacture AAVantgarde’s dual AAV gene therapies for inherited retinal diseases using the high-yield BravoAAV™ suspension platform.